DK3269717T5 - Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 - Google Patents
Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 Download PDFInfo
- Publication number
- DK3269717T5 DK3269717T5 DK17182561.5T DK17182561T DK3269717T5 DK 3269717 T5 DK3269717 T5 DK 3269717T5 DK 17182561 T DK17182561 T DK 17182561T DK 3269717 T5 DK3269717 T5 DK 3269717T5
- Authority
- DK
- Denmark
- Prior art keywords
- nxl104
- polymorphic
- pharmaceutical composition
- pseudopolymorphic forms
- pseudopolymorphic
- Prior art date
Links
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 title 1
- 229960002379 avibactam Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0904864A FR2951171A1 (fr) | 2009-10-09 | 2009-10-09 | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| US26366309P | 2009-11-23 | 2009-11-23 | |
| EP10762934.7A EP2486038B1 (en) | 2009-10-09 | 2010-10-08 | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK3269717T3 DK3269717T3 (en) | 2019-04-23 |
| DK3269717T4 DK3269717T4 (da) | 2023-06-26 |
| DK3269717T5 true DK3269717T5 (da) | 2023-11-27 |
Family
ID=42154208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17182561.5T DK3269717T5 (da) | 2009-10-09 | 2010-10-08 | Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8471025B2 (he) |
| EP (3) | EP3269717B9 (he) |
| JP (4) | JP6072540B2 (he) |
| KR (4) | KR20170134791A (he) |
| CN (3) | CN102834395B (he) |
| AU (1) | AU2010304974B2 (he) |
| BR (2) | BR122019021689B8 (he) |
| CA (1) | CA2716914C (he) |
| CY (1) | CY1121583T1 (he) |
| DK (1) | DK3269717T5 (he) |
| ES (2) | ES2721228T5 (he) |
| FI (1) | FI3269717T4 (he) |
| FR (1) | FR2951171A1 (he) |
| HU (1) | HUE043086T2 (he) |
| IL (3) | IL218565A0 (he) |
| MX (1) | MX2012003730A (he) |
| MY (1) | MY174776A (he) |
| PL (1) | PL3269717T5 (he) |
| PT (1) | PT3269717T (he) |
| RU (1) | RU2727509C2 (he) |
| SI (1) | SI3269717T2 (he) |
| WO (1) | WO2011042560A1 (he) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8247400B2 (en) * | 2009-02-23 | 2012-08-21 | Dedhiya Mahendra G | Cephem compounds useful for the treatment of bacterial infections |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| CN103328476B (zh) * | 2010-12-22 | 2016-12-28 | 明治制果药业株式会社 | 光学活性二氮杂环辛烷衍生物及其制备方法 |
| RU2769076C2 (ru) * | 2011-06-17 | 2022-03-28 | Пфайзер Анти-Инфективз Аб | Способ получения гетероциклических соединений, включая транс-7-оксо-6-(сульфокси)-1,6-диазабицикло[3.2.1]октан-2-карбоксамид и его соли |
| CN103687598B (zh) * | 2011-07-26 | 2016-03-16 | 沃克哈特有限公司 | 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物 |
| JP5666743B2 (ja) * | 2011-08-27 | 2015-02-12 | ウォックハート リミテッド | １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用 |
| US8969567B2 (en) | 2011-09-13 | 2015-03-03 | Wockhardt Ltd. | Nitrogen containing compounds and their use |
| AU2012310136B2 (en) * | 2011-09-13 | 2016-07-07 | Wockhardt Limited | Nitrogen containing compounds and their use |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| KR20150003777A (ko) | 2012-03-30 | 2015-01-09 | 큐비스트 파마슈티컬즈 인코포레이티드 | 이속사졸 β-락타마제 억제제 |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| MX366948B (es) | 2012-05-30 | 2019-07-30 | Meiji Seika Pharma Co Ltd | Nuevo inhibidor de beta-lactamasa y proceso para prepararlo. |
| CN105143226A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 制备(2s,5r)-2-甲酰胺基-7-氧代-6-磺酰氧基-1,6-二氮杂-双环[3.2.1]辛烷的钠盐的方法 |
| US9624222B2 (en) * | 2013-03-08 | 2017-04-18 | Wockhardt Limited | Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octance |
| EP2970338A1 (en) | 2013-03-14 | 2016-01-20 | Merck Sharp & Dohme Corp. | Crystalline form of a beta-lactamase inhibitor |
| HUE049027T2 (hu) * | 2013-09-24 | 2020-08-28 | Meiji Seika Pharma Co Ltd | Diazabiciklooktán-származékok és intermedierek elõállítási eljárása |
| US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| JP6617029B2 (ja) | 2013-10-08 | 2019-12-04 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ジアザビシクロオクタン誘導体の結晶とその製造法 |
| JP2017506240A (ja) * | 2014-02-20 | 2017-03-02 | ウォックハート リミテッド | 抗菌剤を含む医薬組成物 |
| US20170326153A1 (en) | 2014-10-28 | 2017-11-16 | Sandoz Ag | Pharmaceutical Composition Consisting of Ceftaroline Fosamil Acetic Acid Solvate Particles Arginine Particles, Both Having A Specific Particle Size Distribution |
| RS58429B1 (sr) | 2014-11-17 | 2019-04-30 | Entasis Therapeutics Ltd | Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija |
| US10294224B2 (en) | 2014-12-05 | 2019-05-21 | Meiji Seika Pharma Co., Ltd. | Lyophilized composition of a diazabicyclooctane compound and process of producing the same |
| CA2990546A1 (en) * | 2015-08-10 | 2017-02-16 | Sandoz Ag | Form c of avibactam sodium |
| CN107325096B (zh) * | 2016-04-29 | 2020-11-03 | 正大天晴药业集团股份有限公司 | 一种阿维巴坦单钠盐的结晶 |
| AU2017315164B2 (en) * | 2016-08-26 | 2021-12-09 | Sandoz Ag | Avibactam free acid |
| CN114591223A (zh) | 2016-09-16 | 2022-06-07 | 恩塔西斯治疗有限公司 | β-内酰胺酶抑制剂化合物 |
| CN107880042A (zh) * | 2016-09-30 | 2018-04-06 | 上海复星星泰医药科技有限公司 | 阿维巴坦钠及其中间体化合物的制备方法 |
| US10919893B2 (en) | 2017-02-08 | 2021-02-16 | Sandoz Ag | Process for the preparation of crystalline form C of avibactam sodium |
| TWI791018B (zh) | 2017-05-08 | 2023-02-01 | 美商安特西醫療公司 | 治療細菌感染之化合物及方法 |
| WO2019064065A1 (en) * | 2017-09-27 | 2019-04-04 | F. Hoffmann-La Roche Ag | PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| TW201920174A (zh) * | 2017-09-27 | 2019-06-01 | 瑞士商羅氏大藥廠股份有限公司 | 二氮雜雙環辛烷衍生物之醫藥形式及其製法 |
| CA3076959A1 (en) * | 2017-09-27 | 2019-04-04 | Fedora Pharmaceuticals Inc. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
| CN107501265B (zh) * | 2017-10-09 | 2019-05-28 | 台州职业技术学院 | 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用 |
| CN109678856B (zh) | 2017-10-18 | 2020-09-25 | 新发药业有限公司 | 一种阿维巴坦中间体的制备方法 |
| CN107827886B (zh) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | 一种高纯度阿维巴坦的精制制备工艺 |
| CN109956941B (zh) | 2017-12-25 | 2020-08-04 | 新发药业有限公司 | 一种阿维巴坦的简便制备方法 |
| CN107936017A (zh) * | 2018-01-12 | 2018-04-20 | 上海龙翔生物医药开发有限公司 | 一种通过结晶制备晶型a或晶型d阿维巴坦产品的方法 |
| CN107935945A (zh) * | 2018-01-12 | 2018-04-20 | 上海龙翔生物医药开发有限公司 | 一种通过反应制备晶型a或晶型d阿维巴坦产品的方法 |
| CN110078728B (zh) * | 2019-05-23 | 2020-10-23 | 江西富祥药业股份有限公司 | 一种阿维巴坦中间体、制备方法及其应用 |
| CN113105455B (zh) * | 2020-01-10 | 2024-05-17 | 四川科伦药物研究院有限公司 | 晶型b阿维巴坦钠的制备方法 |
| CN111689964A (zh) * | 2020-07-21 | 2020-09-22 | 海南海灵化学制药有限公司 | 一种阿维巴坦纳的稳定晶型以及制备方法 |
| CN115677697A (zh) * | 2022-09-19 | 2023-02-03 | 瑞阳制药股份有限公司 | 粒度可调控且流动性好的b晶型阿维巴坦钠析晶方法 |
| KR20240041506A (ko) * | 2022-09-23 | 2024-04-01 | 주식회사 경보제약 | 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL179435B1 (pl) * | 1993-12-29 | 2000-09-29 | Pfizer | Diazabicykliczni antagonisci neurokininy PL |
| TW473479B (en) | 1997-12-19 | 2002-01-21 | Takeda Chemical Industries Ltd | Phosphonocephem derivatives, their production and use |
| CA2396079A1 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| ES2323759T3 (es) | 2000-08-10 | 2009-07-24 | Takeda Pharmaceutical Company Limited | Compuesto de fosfonocefem. |
| FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| US20080081829A1 (en) * | 2006-09-28 | 2008-04-03 | Med Institute, Inc | Medical Device Including an Anesthetic and Method of Preparation Thereof |
| FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
| EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| MX2012003201A (es) * | 2009-09-21 | 2012-05-08 | Astrazeneca Ab | Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. |
-
2009
- 2009-10-09 FR FR0904864A patent/FR2951171A1/fr active Pending
-
2010
- 2010-10-08 BR BR122019021689A patent/BR122019021689B8/pt active IP Right Grant
- 2010-10-08 EP EP17182561.5A patent/EP3269717B9/en active Active
- 2010-10-08 SI SI201031873T patent/SI3269717T2/sl unknown
- 2010-10-08 MY MYPI2012001576A patent/MY174776A/en unknown
- 2010-10-08 EP EP10762934.7A patent/EP2486038B1/en active Active
- 2010-10-08 BR BR112012007976-0A patent/BR112012007976B1/pt active IP Right Grant
- 2010-10-08 FI FIEP17182561.5T patent/FI3269717T4/fi active
- 2010-10-08 JP JP2012532627A patent/JP6072540B2/ja active Active
- 2010-10-08 RU RU2015137928A patent/RU2727509C2/ru active
- 2010-10-08 CN CN201080045819.XA patent/CN102834395B/zh active Active
- 2010-10-08 WO PCT/EP2010/065147 patent/WO2011042560A1/en active Application Filing
- 2010-10-08 CN CN201410836227.XA patent/CN104592229A/zh active Pending
- 2010-10-08 ES ES17182561T patent/ES2721228T5/es active Active
- 2010-10-08 ES ES10762934.7T patent/ES2645110T3/es active Active
- 2010-10-08 US US12/900,567 patent/US8471025B2/en active Active
- 2010-10-08 MX MX2012003730A patent/MX2012003730A/es active IP Right Grant
- 2010-10-08 CN CN201910137306.4A patent/CN109824668A/zh active Pending
- 2010-10-08 KR KR1020177034526A patent/KR20170134791A/ko not_active Application Discontinuation
- 2010-10-08 KR KR1020127009004A patent/KR101817811B1/ko active IP Right Grant
- 2010-10-08 HU HUE17182561A patent/HUE043086T2/hu unknown
- 2010-10-08 EP EP19151839.8A patent/EP3505518A1/en active Pending
- 2010-10-08 CA CA2716914A patent/CA2716914C/en active Active
- 2010-10-08 KR KR1020207001713A patent/KR20200010586A/ko not_active IP Right Cessation
- 2010-10-08 AU AU2010304974A patent/AU2010304974B2/en active Active
- 2010-10-08 PL PL17182561.5T patent/PL3269717T5/pl unknown
- 2010-10-08 KR KR1020187016242A patent/KR20180067717A/ko active Search and Examination
- 2010-10-08 PT PT17182561T patent/PT3269717T/pt unknown
- 2010-10-08 DK DK17182561.5T patent/DK3269717T5/da active
-
2012
- 2012-03-08 IL IL218565A patent/IL218565A0/en unknown
-
2013
- 2013-05-24 US US13/901,724 patent/US8835455B2/en active Active
-
2014
- 2014-08-07 US US14/454,141 patent/US9062053B2/en active Active
-
2015
- 2015-05-13 US US14/711,162 patent/US9580424B2/en active Active
- 2015-06-25 IL IL239663A patent/IL239663A0/he unknown
- 2015-10-09 JP JP2015201555A patent/JP6197170B2/ja active Active
-
2017
- 2017-01-13 US US15/405,409 patent/US20170210742A1/en not_active Abandoned
- 2017-04-14 JP JP2017080380A patent/JP6321853B2/ja active Active
-
2018
- 2018-04-04 JP JP2018072510A patent/JP6630391B2/ja active Active
- 2018-05-13 IL IL259296A patent/IL259296B/he unknown
-
2019
- 2019-04-25 CY CY20191100453T patent/CY1121583T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3269717T5 (da) | Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| DK2513193T3 (da) | Forbedrede blends af polyarylenethere og polyarylensulfider | |
| DK3460056T3 (da) | Terapeutiske nukleasesammensætninger og fremgangsmåder | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| DK3045043T3 (da) | Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse | |
| BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
| FR22C1023I1 (fr) | Forme polymorphe st-246 et procedes de preparation | |
| DK2220116T3 (da) | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| DK2498756T3 (da) | Tabletformuleringer af neratinibmaleat | |
| DK2264042T3 (da) | Mikronisering af polyoler | |
| DK2419732T3 (da) | Prionfrie nanopartikelsammensætninger og fremgangsmåder | |
| DK3092901T3 (da) | Quinolonanaloger og fremgangsmåder relateret dertil | |
| BRPI0810179A2 (pt) | Composições de oligo-guluronato e galacturonato | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| BRPI1012539A2 (pt) | composições farmacêuticas | |
| DK3260118T3 (da) | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion | |
| FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
| BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
| BRPI1006229A2 (pt) | composição incluindo uma quantidade suficiente de curcumina | |
| BR112012010242A2 (pt) | derivados de heteroarilpiperidina e heteroarilpiperazina | |
| IT1394400B1 (it) | Composizioni farmaceutiche | |
| DK2475649T3 (da) | Indenonderivat og farmaceutisk sammensætning omfattende samme |